The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer

C. Aristei; O. Kaidar-Person; L. Boersma; M. C. Leonardi; B. Offersen; P. Franco; M. Arenas; C. Bourgier; R. Pfeffer; V. Kouloulias; Y. Bölükbasi; I. Meattini; C. Coles; A. Montero Luis; V. Masiello; I. Palumbo; A. G. Morganti; E. Perrucci; V. Tombolini; M. Krengli; F. Marazzi; L. Trigo; S. Borghesi; A. Ciabattoni; I. Ratoša; V. Valentini; P. Poortmans

doi:10.1016/j.critrevonc.2023.104035

The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer

C. Aristei^*, O. Kaidar-Person, L. Boersma, M. C. Leonardi, B. Offersen, P. Franco, M. Arenas, C. Bourgier, R. Pfeffer, V. Kouloulias, Y. Bölükbasi, I. Meattini, C. Coles, A. Montero Luis, V. Masiello, I. Palumbo, A. G. Morganti, E. Perrucci, V. Tombolini, M. KrengliF. Marazzi, L. Trigo, S. Borghesi, A. Ciabattoni, I. Ratoša, V. Valentini, P. Poortmans

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.

Original language	English
Article number	104035
Number of pages	16
Journal	Critical Reviews in Oncology/Hematology
Volume	187
Issue number	1
DOIs	https://doi.org/10.1016/j.critrevonc.2023.104035
Publication status	Published - 1 Jul 2023

Keywords

Breast cancer
Combined modality treatment
Immunotherapy
Radiation therapy
Re-irradiation in relapsed patients

Access to Document

10.1016/j.critrevonc.2023.104035Licence: CC BY-NC-ND

Cite this

Aristei, C., Kaidar-Person, O., Boersma, L., Leonardi, M. C., Offersen, B., Franco, P., Arenas, M., Bourgier, C., Pfeffer, R., Kouloulias, V., Bölükbasi, Y., Meattini, I., Coles, C., Luis, A. M., Masiello, V., Palumbo, I., Morganti, A. G., Perrucci, E., Tombolini, V., ... Poortmans, P. (2023). The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer. Critical Reviews in Oncology/Hematology, 187(1), Article 104035. https://doi.org/10.1016/j.critrevonc.2023.104035

@article{991d00f425d04a5dbb20540167f3baa6,

title = "The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer",

abstract = "The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.",

keywords = "Breast cancer, Combined modality treatment, Immunotherapy, Radiation therapy, Re-irradiation in relapsed patients",

author = "C. Aristei and O. Kaidar-Person and L. Boersma and Leonardi, {M. C.} and B. Offersen and P. Franco and M. Arenas and C. Bourgier and R. Pfeffer and V. Kouloulias and Y. B{\"o}l{\"u}kbasi and I. Meattini and C. Coles and Luis, {A. Montero} and V. Masiello and I. Palumbo and Morganti, {A. G.} and E. Perrucci and V. Tombolini and M. Krengli and F. Marazzi and L. Trigo and S. Borghesi and A. Ciabattoni and I. Rato{\v s}a and V. Valentini and P. Poortmans",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = jul,

day = "1",

doi = "10.1016/j.critrevonc.2023.104035",

language = "English",

volume = "187",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Science",

number = "1",

}

Aristei, C, Kaidar-Person, O, Boersma, L, Leonardi, MC, Offersen, B, Franco, P, Arenas, M, Bourgier, C, Pfeffer, R, Kouloulias, V, Bölükbasi, Y, Meattini, I, Coles, C, Luis, AM, Masiello, V, Palumbo, I, Morganti, AG, Perrucci, E, Tombolini, V, Krengli, M, Marazzi, F, Trigo, L, Borghesi, S, Ciabattoni, A, Ratoša, I, Valentini, V & Poortmans, P 2023, 'The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer', Critical Reviews in Oncology/Hematology, vol. 187, no. 1, 104035. https://doi.org/10.1016/j.critrevonc.2023.104035

TY - JOUR

T1 - The 2022 Assisi Think Tank Meeting

T2 - White paper on optimising radiation therapy for breast cancer

AU - Aristei, C.

AU - Kaidar-Person, O.

AU - Boersma, L.

AU - Leonardi, M. C.

AU - Offersen, B.

AU - Franco, P.

AU - Arenas, M.

AU - Bourgier, C.

AU - Pfeffer, R.

AU - Kouloulias, V.

AU - Bölükbasi, Y.

AU - Meattini, I.

AU - Coles, C.

AU - Luis, A. Montero

AU - Masiello, V.

AU - Palumbo, I.

AU - Morganti, A. G.

AU - Perrucci, E.

AU - Tombolini, V.

AU - Krengli, M.

AU - Marazzi, F.

AU - Trigo, L.

AU - Borghesi, S.

AU - Ciabattoni, A.

AU - Ratoša, I.

AU - Valentini, V.

AU - Poortmans, P.

PY - 2023/7/1

Y1 - 2023/7/1

N2 - The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.

AB - The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1–2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1–3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.

KW - Breast cancer

KW - Combined modality treatment

KW - Immunotherapy

KW - Radiation therapy

KW - Re-irradiation in relapsed patients

U2 - 10.1016/j.critrevonc.2023.104035

DO - 10.1016/j.critrevonc.2023.104035

M3 - (Systematic) Review article

C2 - 37244324

SN - 1040-8428

VL - 187

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 1

M1 - 104035

ER -